This page in English

Taher Darreh-Shori



08-585 836 12


Organisatorisk tillhörighet

Sektionen för translationell alzheimer neurobiologi


Institutionen för Neurobiologi, Vårdvetenskap och Samhälle (NVS), H1

Besöksadress : Novum Pl 5, Hälsovägen7/Blickagången 6 141 57 Huddinge
Postadress : Institutionen för Neurobiologi, Vårdvetenskap och Samhälle (NVS), H1, Sektionen för translationell alzheimer neurobiologi, Novum Pl 5, Blickagången 6/Hälsovägen 7 141 57 Huddinge
Leveransadress : Hälsovägen 7 141 57 Huddinge


Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor
Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B, et al
Journal of Alzheimer's disease : JAD 2015;43(3):1059-72

Complement component c3 and butyrylcholinesterase activity are associated with neurodegeneration and clinical disability in multiple sclerosis
Aeinehband S, Lindblom Rp, Al Nimer F, Vijayaraghavan S, Sandholm K, Khademi M, et al
PloS one 2015;10(4):e0122048-

Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value
Lane Rm, Darreh-shori T
Journal of Alzheimer's disease : JAD 2015;44(4):1039-62

Association of APOE4 and BCHE-K genotypes with diagnosis and cognitive decline in dementia patients
Vijayaraghavan S, Darreh-shori T, Rongve A, Berge G, Sando Sb, White Lr, et al

Fibrillar ss-amyloid 1-42 alters cytokine secretion, cholinergic signalling and neuronal differentiation
Malmsten L, Vijayaraghavan S, Hovatta O, Marutle A, Darreh-shori T
Journal of cellular and molecular medicine 2014;18(9):1874-88

High apolipoprotein E in cerebrospinal fluid of patients with Lewy body disorders is associated with dementia
Vijayaraghavan S, Maetzler W, Reimold M, Lithner Cu, Liepelt-scarfone I, Berg D, et al
Alzheimer's & dementia : the journal of the Alzheimer's Association 2014;10(5):530-540.e1

Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors
Darreh-shori T, Hosseini Sm, Nordberg A
Journal of Alzheimer's disease : JAD 2014;39(2):423-40

Unbiased expression mapping identifies a link between the complement and cholinergic systems in the rat central nervous system
Lindblom Rp, Strom M, Heinig M, Al Nimer F, Aeinehband S, Berg A, et al
Journal of immunology (Baltimore, Md. : 1950) 2014;192(3):1138-53

A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease
Nordberg A, Ballard C, Bullock R, Darreh-shori T, Somogyi M
The primary care companion for CNS disorders 2013;15(2):-

Biomarkers in Alzheimer's disease and lewy body disorders with dementia
Leyhe T, Darreh-shori T, Laske C, Mielke Mm, Maetzler W
International journal of Alzheimer's disease 2013;2013():473181-

Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
Darreh-shori T, Vijayaraghavan S, Aeinehband S, Piehl F, Lindblom Rp, Nilsson B, et al
Neurobiology of aging 2013;34(11):2465-81

Regulated Extracellular Choline Acetyltransferase Activity- The Plausible Missing Link of the Distant Action of Acetylcholine in the Cholinergic Anti-Inflammatory Pathway
Vijayaraghavan S, Karami A, Aeinehband S, Behbahani H, Grandien A, Nilsson B, et al
PLOS ONE 2013;8(6):-

Apolipoprotein ?4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease
Darreh-shori T, Siawesh M, Mousavi M, Andreasen N, Nordberg A
Journal of Alzheimer's disease : JAD 2012;28(2):443-58

Cell therapy with NGF in patients with Alzheimer's disease: changes in CSF cholinergic markers
Karami A, Eyjolfsdottir H, Vijayaraghavan S, Kadir A, Linderoth B, Lind G, et al

Darreh-shori T

Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
Darreh-shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, et al
Neurobiology of aging 2011;32(12):2320.e15-32

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
Kadir A, Marutle A, Gonzalez D, Scholl M, Almkvist O, Mousavi M, et al
Brain : a journal of neurology 2011;134(Pt 1):301-17

The apolipoprotein E ?4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase
Darreh-shori T, Modiri N, Blennow K, Baza S, Kamil C, Ahmed H, et al
Neurobiology of aging 2011;32(7):1236-48

Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies
Darreh-shori T, Soininen H
Current Alzheimer research 2010;7(1):67-73

Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study
Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-shori T, Basu S, et al
Dementia and geriatric cognitive disorders 2010;29(3):204-12

Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
Darreh-shori T, Jelic V
Expert opinion on drug safety 2010;9(1):167-76

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Nordberg A, Darreh-shori T, Peskind E, Soininen H, Mousavi M, Eagle G, et al
Current Alzheimer research 2009;6(1):4-14

Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment
Ferris S, Nordberg A, Soininen H, Darreh-shori T, Lane R
Pharmacogenetics and genomics 2009;19(8):635-46

Safety of lumbar puncture procedures in patients with Alzheimer's disease
Peskind E, Nordberg A, Darreh-shori T, Soininen H
Current Alzheimer research 2009;6(3):290-2

Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine
Darreh-shori T, Kadir A, Almkvist O, Grut M, Wall A, Blomquist G, et al
Neurobiology of aging 2008;29(2):168-84

PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD
Kadir A, Darreh-shori T, Almkvist O, Wall A, Grut M, Strandberg B, et al
Neurobiology of aging 2008;29(8):1204-17

Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's disease
Lane R, Feldman Hh, Meyer J, He Y, Ferris Sh, Nordberg A, et al
Pharmacogenetics and genomics 2008;18(4):289-98

The effect of cholinesterase inhibitors on the levels and activities of cholinesterases in the cerebrospinal fluid of Alzheimer's disease patients
Farlow M, Darreh-shori T, Peskind E, Alva G, Eagle G, Nordberg A
NEUROLOGY 2008;70(11):A99-A99

The effects of ChEIs on CSF cholinesterase activity in AD patients
Farlow M, Darreh-shori T, Peskind E, Brannan S, Nordberg A

Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET
Kadir A, Darreh-shori T, Almkvist O, Wall A, Langstrom B, Nordberg A
Psychopharmacology 2007;191(4):1005-14

Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment
Darreh-shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-lindahl E, Andreasen N, et al
Journal of neural transmission (Vienna, Austria : 1996) 2006;113(11):1791-801

Differential CSF butyrylcholinesterase levels in Alzheimer's disease patients with the ApoE epsilon4 allele, in relation to cognitive function and cerebral glucose metabolism
Darreh-shori T, Brimijoin S, Kadir A, Almkvist O, Nordberg A
Neurobiology of disease 2006;24(2):326-33

Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients
Darreh-shori T, Hellstrom-lindahl E, Flores-flores C, Guan Zz, Soreq H, Nordberg A
Journal of neurochemistry 2004;88(5):1102-13

Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients
Almkvist O, Darreh-shori T, Stefanova E, Spiegel R, Nordberg A
European journal of neurology : the official journal of the European Federation of Neurological Societies 2004;11(4):253-61

Long-term changes in the protein levels of different acetylcholinesterase (ACHE) isoforms in cerebrospinal fluid (CSF) of rivastigmine and tacrine treated AD patients
Darreh-shori T, Nordberg A, Hellstrom-lindahl E, Flores-flores C, Soreq H
NEUROBIOLOGY OF AGING 2002;23(1):S375-S375

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months
Darreh-shori T, Almkvist O, Guan Zz, Garlind A, Strandberg B, Svensson Al, et al
Neurology 2002;59(4):563-72

Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms
Djerbi M, Darreh-shori T, Zhivotovsky B, Grandien A
Scandinavian journal of immunology 2001;54(1-2):180-9

Visa alla publikationer